Food and Drug Administration
approval to market
as a treatment for certain forms of multiple sclerosis.
Novantrone is currently marketed, in combination with corticosteroids, to treat pain in patients with advanced hormone-refractory prostate cancer and for an initial therapy of acute nonlymphocytic leukemia.
The FDA approval allows Immunex to promote Novantrone as a treatment for secondary progressive multiple sclerosis.
Shares of Immunex recently traded up $1.25, or 3.3%, to $38.88 in
in midday trading.